GILD · Healthcare

GILEAD SCIENCES, INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Remdesivir Ebola DeploymentImportance 25 · Surprise 42
  Health authorities in eastern Democratic Republic of Congo are broadening use of Gilead’s antiviral remdesivir during a worsening Bundibugyo-strain Ebola outbreak. The outbreak reportedly reached nearly 4,000 cases and…

News · 2026-08-07

• Capital Return ProgramImportance 33 · Surprise 42
  Gilead repurchased 2,693,030 shares for $355 million between April 1 and June 30, 2026. Cumulative repurchases under the February 25, 2020 buyback plan reached 51,569,874 shares, or 4.14% of equity. Total repurchase…

10-Q · 2026-08-06

• Liquidity and Cash PositionImportance 89 · Surprise 82
  Cash and cash equivalents were $3.2 billion as of June 30, 2026. Operating cash flow increased to $6.1 billion for the first six months from $2.6 billion in the prior-year period, supported by lower tax payments,…
• Operating Expense TrendsImportance 78 · Surprise 74
  Selling, general and administrative expense increased 41% to $1.9 billion in the second quarter of 2026 and 29% to $3.4 billion for the first six months. Selling and marketing expense rose primarily because of higher…
• In-Process R&D ImpairmentImportance 71 · Surprise 60
  Gilead recognized a $1.75 billion pre-tax impairment charge in the second quarter of 2026 for the Immunomedics-acquired NSCLC in-process research and development asset. The charge followed discontinuation of the Phase…
• Research and Development ExpenseImportance 68 · Surprise 58
  Research and development expense increased 18% to $1.8 billion in the second quarter of 2026 and 9% to $3.1 billion for the first six months. Personnel, infrastructure and other support costs increased primarily…
• Income Tax Rate ChangesImportance 59 · Surprise 82
  The effective tax rate declined to negative 2.4% in the second quarter of 2026 from 19.3% in the prior-year quarter. For the first six months, the effective tax rate declined to negative 10.4% from 19.7%. The change…
• Competition and Market Share PressureImportance 56 · Surprise 58
  Cell Therapy product sales declined 14% in the second quarter and 13% for the first six months of 2026. Gilead attributed the decline primarily to lower demand reflecting ongoing competitive headwinds, indicating…
• Revenue Performance and MixImportance 54 · Surprise 40
  Total revenues increased 10% to $7.8 billion in the second quarter of 2026 and 7% to $14.8 billion in the first six months, primarily from higher HIV, Trodelvy, Livdelzi, royalty, contract and other revenues. HIV…
• Market Demand TrendsImportance 54 · Surprise 40
  HIV product sales increased 12% to $5.7 billion in the three months ended June 30, 2026 and 11% to $10.7 billion in the six months, driven by higher demand and average realized price. Biktarvy benefited from demand…
• Acquisition / Partnership / DivestitureImportance 53 · Surprise 60
  Gilead completed its acquisition of Arcellx, adding the anitocabtagene autoleucel program for relapsed or refractory multiple myeloma and a D-Domain BCMA binder. Gilead completed the Tubulis acquisition, adding TUB-040…
• Gross Margin DriversImportance 49 · Surprise 32
  Product gross margin was 79.3% in the second quarter of 2026, compared with 78.7% in the prior-year quarter. Six-month product gross margin increased to 79.3% from 77.7%, a 150-basis-point improvement. The year-to-date…
• Product / Drug Pipeline ProgressImportance 47 · Surprise 60
  Gilead is expanding its HIV prevention and treatment portfolio, with FDA acceptance of a supplemental NDA for once-weekly oral Yeztugo and an NDA for bictegravir and lenacapavir under priority review. Hepcludex…
• Regulatory Approval MilestonesImportance 47 · Surprise 60
  The FDA accepted Gilead’s supplemental NDA for a once-weekly oral Yeztugo formulation for HIV pre-exposure prophylaxis, with a PDUFA target action date of February 2, 2027. FDA also granted accelerated approval for…
• Product Launch and TransitionImportance 40 · Surprise 42
  Yeztugo generated product sales in the second quarter and first half of 2026, with growth primarily attributed to higher demand. The product is being developed as a once-weekly oral HIV pre-exposure prophylaxis…
• Geographic Market CommentaryImportance 37 · Surprise 6
  Gilead sells products across the U.S., Europe and Rest of World markets and operates in more than 35 countries. For the six months ended June 30, 2026, product sales were $10.5 billion in the U.S., $2.3 billion in…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Gilead’s Board declared a quarterly dividend of $0.82 per common share in August 2026. The dividend is payable September 29, 2026. Shareholders of record at the close of business on September 15, 2026 will receive the…

News · 2026-08-06

• Acquisition-Related R&D ChargesImportance 96 · Surprise 100
  Gilead swung to a second-quarter net loss of approximately $10.5 billion, compared with net income of $2.01 per diluted share in the year-ago quarter. The loss was primarily driven by acquired in-process research and…
• Free Cash Flow and LiquidityImportance 44 · Surprise 24
  Gilead generated approximately $3.4 billion of free cash flow in the second quarter of 2026. The reported cash generation provided support for ongoing capital returns despite the quarter’s acquisition-related…

News · 2026-08-05

• Trodelvy and Livdelzi DemandImportance 50 · Surprise 58
  Gilead identified Trodelvy in oncology and Livdelzi in liver disease as additional contributors to base-business growth. These products complemented the HIV portfolio in driving 10% year-over-year base-business sales…
• HIV and PrEP Demand GrowthImportance 48 · Surprise 40
  Gilead’s HIV portfolio generated 12% year-over-year sales growth in the second quarter, reflecting continued strength in treatment products and rapid expansion of its PrEP business. HIV prevention medicines exceeded $1…

8-K · 2026-08-04

• Guidance / OutlookImportance 95 · Surprise 92
  Gilead raised 2026 product-sales guidance to $30.1 billion-$30.4 billion from $30.0 billion-$30.4 billion previously. Product sales excluding Veklury guidance increased to $29.8 billion-$30.1 billion from $29.4…
• Guidance and OutlookImportance 95 · Surprise 92
  Gilead raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion from $30.0 billion-$30.4 billion previously. Product sales excluding Veklury guidance increased to $29.8 billion-$30.1 billion from $29.4…
• Operating Margin DriversImportance 90 · Surprise 100
  GAAP operating loss was $10.394 billion in the second quarter of 2026 versus operating income of $2.474 billion in the prior-year quarter, producing a negative 133.2% operating margin versus 34.9%. The loss primarily…
• Operating Expense TrendsImportance 72 · Surprise 74
  GAAP R&D expense increased 18% year over year to $1.764 billion from $1.491 billion, primarily due to integration costs and other acquisition-related expenses, partly offset by lower oncology clinical study activity.…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Gilead completed the Tubulis acquisition for $3.15 billion of upfront consideration, adding the GS-8824 NaPi2b-directed topoisomerase-I inhibitor ADC and an ADC development platform. Gilead completed the Ouro Medicines…
• Acquisitions and PartnershipsImportance 71 · Surprise 60
  Gilead completed its acquisition of Tubulis for $3.15 billion in upfront consideration, adding antibody-drug conjugate assets including GS-8824 and an ADC development platform. It also completed the acquisition of Ouro…
• Outstanding IndebtednessImportance 69 · Surprise 50
  Gilead issued $3.0 billion of senior unsecured notes during the quarter. Gilead also borrowed $1.1 billion under a one-year term loan facility. The company reported $2.8 billion of year-to-date debt repayments and $4.1…
• Liquidity and Cash PositionImportance 64 · Surprise 42
  Cash, cash equivalents and marketable debt securities declined to $3.179 billion at June 30, 2026 from $10.605 billion at December 31, 2025. Year-to-date cash outflows included $11.3 billion for acquisitions, $2.8…
• Market Demand TrendsImportance 64 · Surprise 56
  Total product sales excluding Veklury increased 10% year over year to $7.6 billion in the second quarter of 2026. HIV product sales rose 12% to $5.7 billion, driven by higher average realized price and demand. Biktarvy…
• Financing ActivitiesImportance 64 · Surprise 42
  Gilead issued $3.0 billion aggregate principal amount of senior unsecured notes. It also borrowed $1.1 billion under a one-year term loan facility. These financings occurred alongside $11.3 billion of year-to-date…
• Geographic Market CommentaryImportance 57 · Surprise 38
  Second-quarter product sales totaled $5.6 billion in the U.S., $1.2 billion in Europe and $872 million in the Rest of World. U.S. HIV sales were $4.7 billion, including $3.0 billion of Biktarvy and $921 million of…
• Product Sales PerformanceImportance 52 · Surprise 56
  Biktarvy sales increased 7% year over year to $3.8 billion, driven by higher average realized price, favorable inventory dynamics and higher demand. Descovy sales increased 48% to $967 million, primarily because of…
• Competition and Market ShareImportance 48 · Surprise 40
  Cell Therapy product sales decreased 14% to $417 million because of ongoing competitive headwinds. Yescarta sales fell 12% to $346 million, primarily due to both in-class and out-of-class competition. Tecartus sales…
• Product / Drug Pipeline ProgressImportance 47 · Surprise 60
  Gilead received FDA accelerated approval for Hepcludex, making it the first and only FDA-approved treatment for chronic hepatitis delta virus infection in the U.S. The FDA accepted a supplemental application for a…
• Revenue Performance and MixImportance 43 · Surprise 32
  Second-quarter 2026 total revenue increased 10% year over year to $7.803 billion from $7.082 billion, including $7.627 billion of product sales and $176 million of royalty, contract and other revenue. Product sales…
• Income Tax Rate ChangesImportance 40 · Surprise 56
  The GAAP effective tax rate declined to negative 2.4% in the second quarter of 2026 from 19.3% in the prior-year quarter. The non-GAAP effective tax rate declined to negative 11.4% from 18.8%. The change primarily…
• Capital Return ProgramImportance 37 · Surprise 6
  Gilead paid $1.0 billion of dividends and repurchased $355 million of common stock during the second quarter of 2026. Year-to-date dividend payments totaled $2.1 billion, and common-stock repurchases totaled $774…
• Oncology Product ExpansionImportance 31 · Surprise 42
  Gilead received FDA approval for Trodelvy in first-line unresectable locally advanced or metastatic triple-negative breast cancer. The approval covers monotherapy for patients who are not candidates for PD-1/PD-L1…
• Regulatory Approval MilestonesImportance 31 · Surprise 42
  The U.S. FDA accepted Gilead's supplemental New Drug Application for a potential once-weekly oral Yeztugo formulation for HIV PrEP, with a Prescription Drug User Fee Act target action date of February 2, 2027. The FDA…
• Gross Margin DriversImportance 13 · Surprise 6
  GAAP product gross margin increased to 79.3% in the second quarter of 2026 from 78.7% in the prior-year quarter. Non-GAAP product gross margin was unchanged at 86.9% year over year. Six-month GAAP product gross margin…

News · 2026-08-04

• Acquisition-Related R&D ChargesImportance 96 · Surprise 100
  Gilead swung to a second-quarter net loss of approximately $10.5 billion, compared with net income of $2.01 per diluted share in the year-ago quarter. The loss was primarily driven by acquired in-process research and…
• Guidance / OutlookImportance 82 · Surprise 100
  Gilead raised its 2026 base-business and product-sales outlook after second-quarter strength in HIV treatment and prevention products, Trodelvy, and Livdelzi. HIV growth expectations were increased, while HIV…
• Veklury Sales DeclineImportance 76 · Surprise 100
  Second-quarter Veklury sales declined 81% year over year. The decline reduced growth in total product sales to 8%, versus 10% growth for product sales excluding Veklury. Gilead lowered its full-year 2026 forecast for…
• Litigation and Legal RiskImportance 59 · Surprise 60
  On August 4, 2026, the California Supreme Court ruled for Gilead Sciences in litigation involving HIV-drug patients. The court held that manufacturers of safe, nondefective drugs do not have a duty to innovate or…
• Trodelvy and Livdelzi DemandImportance 50 · Surprise 58
  Gilead identified Trodelvy in oncology and Livdelzi in liver disease as additional contributors to base-business growth. These products complemented the HIV portfolio in driving 10% year-over-year base-business sales…
• Revenue Performance and MixImportance 48 · Surprise 40
  Gilead’s second-quarter 2026 total revenue increased 10% year over year to $7.8 billion from $7.08 billion. Product sales excluding Veklury rose 10% year over year to $7.6 billion, while total product sales including…
• HIV and PrEP Demand GrowthImportance 48 · Surprise 40
  Gilead’s HIV portfolio generated 12% year-over-year sales growth in the second quarter, reflecting continued strength in treatment products and rapid expansion of its PrEP business. HIV prevention medicines exceeded $1…
• Free Cash Flow and LiquidityImportance 44 · Surprise 24
  Gilead generated approximately $3.4 billion of free cash flow in the second quarter of 2026. The reported cash generation provided support for ongoing capital returns despite the quarter’s acquisition-related…
• Capital Return ProgramImportance 33 · Surprise 42
  Gilead repurchased 2,693,030 shares for $355 million between April 1 and June 30, 2026. Cumulative repurchases under the February 25, 2020 buyback plan reached 51,569,874 shares, or 4.14% of equity. Total repurchase…